Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-01-24
2006-01-24
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S237800, C514S398000, C514S399000, C514S563000, C544S162000, C544S402000, C546S224000, C546S309000, C548S371400, C548S567000, C562S444000, C562S449000
Reexamination Certificate
active
06989402
ABSTRACT:
New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2and R3are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2and R3being other than hydrogen; R4is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.
REFERENCES:
patent: 4741897 (1988-05-01), Andrews et al.
patent: 6395784 (2002-05-01), Ryono
patent: 32 31 541 (1994-03-01), None
patent: 0 580 550 (1994-01-01), None
patent: WO 96/40048 (1996-02-01), None
M. Adamczyk, et al: Bioconjugate Chem., vol. 8, No. 2, pp. 133-145, XP000906993 (1997).
M. Andre, et al: J. Chromatogr. A, vol. 725, No. 2, pp. 287-294, XP004039616 (1996).
Database Chemabs [Online} Chemical Abstracts Service, Columbus, Ohio, US STN, Caplus accession No. 1971:540431, XP002139408—& Chemical Abstracts, vol. 75, No. 23, Dec. 6, 1971 Columbus, Ohio US; abstract No. 140431, XP002139407 & K. Masuda et al: Takeda Kenkyusho Ho, vol. 29, No. 4, pp. 545-552 (1970).
Caringal Yolanda
Collazo Ana Maria Garcia
Garg Neeraj
Hangeland Jon
Koehler Konrad
Coppins Janet L.
Garabedian Todd E.
Karo Bio AB
McKane Joseph K.
Wiggin and Dana LLP
LandOfFree
Thyroid receptor ligands and method II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thyroid receptor ligands and method II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thyroid receptor ligands and method II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3568716